Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027
Cartesian Therapeutics secured a $150 million non-dilutive credit facility from K2 HealthVentures, with an initial $50 million tranche funded immediately. This financing extends the company’s cash runway into 2028, providing sufficient capital to support three near-term clinical data readouts in 2027 and pre-commercial launch activities for its lead asset, Descartes-08. Topline data from the pivotal Phase 3 AURORA trial in myasthenia gravis is expected in Q1 2027, with a BLA filing planned for mid-2027. Data from Phase 2 and Phase 1/2 trials in myositis and juvenile dermatomyositis are also expected in the first half of 2027.
Key figures
- Deal Value Usd
- 150000000
- Third tranche
- 25000000
- Second tranche
- 25000000
- Initial tranche
- 50000000
- Optional tranche
- 50000000
- Cash runway extension
- 2028
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.